JPMorgan Chase & Co. Analysts Give AstraZeneca (LON:AZN) a GBX 7,900 Price Target
JPMorgan Chase & Co. set a GBX 7,900 ($103.23) price objective on AstraZeneca (LON:AZN) in a report published on Monday morning, Borsen Zeitung reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.
A number of other brokerages have also recently issued reports on AZN. Jefferies Financial Group reaffirmed a neutral rating on shares of AstraZeneca in a research note on Thursday, August 29th. Goldman Sachs Group set a GBX 5,500 ($71.87) target price on shares of AstraZeneca and gave the stock a sell rating in a research report on Monday, September 2nd. Shore Capital reissued a buy rating on shares of AstraZeneca in a research note on Tuesday, August 27th. Liberum Capital restated a hold rating and set a GBX 6,400 ($83.63) price target on shares of AstraZeneca in a research report on Wednesday, August 28th. Finally, UBS Group restated a sell rating on shares of AstraZeneca in a research report on Wednesday, August 21st. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of GBX 6,956.25 ($90.90).
AZN stock opened at GBX 6,917 ($90.38) on Monday. The company has a market capitalization of $90.74 billion and a PE ratio of 40.40. AstraZeneca has a one year low of GBX 5,312 ($69.41) and a one year high of GBX 7,583 ($99.09). The company’s 50 day moving average price is GBX 7,124.24 and its two-hundred day moving average price is GBX 6,384.29. The company has a debt-to-equity ratio of 144.48, a quick ratio of 0.74 and a current ratio of 0.95.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: Index Funds
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.